Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LORL
2101
DELISTED
Loral Space and Communications, Inc.
LORL
| $3.16M | ﹤0.01% |
97,700
+19,000
| +24% | +$697K |
|
|
PRFT
2102
DELISTED
Perficient Inc
PRFT
| $3.15M | ﹤0.01% |
+68,393
| New | +$2.79M |
|
2103
Agree Realty
ADC
$9.34B
| $3.14M | ﹤0.01% |
+44,800
| New | +$3.3M |
|
2104
Espey Mfg & Electronics Corp
ESP
$177M
| $3.13M | ﹤0.01% |
145,087
-1,900
| -1% | -$41.9K |
|
2105
Mustang Bio
MBIO
$4.32M
| $3.13M | ﹤0.01% |
1,023
+86
| +9% | +$197K |
|
|
CTIC
2106
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $3.11M | ﹤0.01% |
1,967,914
+90,025
| +5% | +$85.3K |
|
2107
Banner Corp
BANR
$2.39B
| $3.11M | ﹤0.01% |
54,900
+20,801
| +61% | +$1.15M |
|
2108
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.83B
| $3.11M | ﹤0.01% |
88,000
+54,600
| +163% | +$1.88M |
|
|
RDFN
2109
DELISTED
Redfin
RDFN
| $3.09M | ﹤0.01% |
+146,200
| New | +$2.8M |
|
2110
Ecovyst
ECVT
$1.32B
| $3.08M | ﹤0.01% |
179,400
+21,200
| +13% | +$340K |
|
2111
Superior Group of Companies
SGC
$185M
| $3.08M | ﹤0.01% |
227,600
+4,300
| +2% | +$62.1K |
|
2112
Karyopharm Therapeutics
KPTI
$43.5M
| $3.08M | ﹤0.01% |
+10,700
| New | +$2.32M |
|
|
FCCY
2113
DELISTED
1st Constitution Bancorp
FCCY
| $3.08M | ﹤0.01% |
138,953
+13,153
| +10% | +$263K |
|
|
VNTR
2114
DELISTED
Venator Materials PLC
VNTR
| $3.07M | ﹤0.01% |
800,853
+172,715
| +27% | +$562K |
|
|
WWE
2115
DELISTED
World Wrestling Entertainment
WWE
| $3.06M | ﹤0.01% |
47,214
-1,573,700
| -97% | -$99.5M |
|
2116
Texas Roadhouse
TXRH
$13.5B
| $3.06M | ﹤0.01% |
54,372
-324,500
| -86% | -$17.8M |
|
|
CSLT
2117
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $3.06M | ﹤0.01% |
2,299,550
+469,950
| +26% | +$656K |
|
|
CDTX
2118
DELISTED
Cidara Therapeutics
CDTX
| $3.06M | ﹤0.01% |
39,783
+5,999
| +18% | +$275K |
|
|
TCO
2119
DELISTED
Taubman Centers Inc.
TCO
| $3.05M | ﹤0.01% |
+98,100
| New | +$3.36M |
|
|
SCX
2120
DELISTED
The L.S. Starrett Company
SCX
| $3.04M | ﹤0.01% |
532,076
+42,855
| +9% | +$243K |
|
2121
Friedman Industries
FRD
$240M
| $3.04M | ﹤0.01% |
504,120
+10,100
| +2% | +$64.6K |
|
2122
TETRA Technologies
TTI
$1.14B
| $3.03M | ﹤0.01% |
1,547,606
+405,890
| +36% | +$653K |
|
|
LBC
2123
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $3.03M | ﹤0.01% |
262,868
+66,002
| +34% | +$751K |
|
2124
British American Tobacco
BTI
$131B
| $3.02M | ﹤0.01% |
71,234
-218,000
| -75% | -$8.22M |
|
2125
Veru
VERU
$36M
| $3.02M | ﹤0.01% |
90,291
+50,760
| +128% | +$1.13M |
|
Similar funds
Renaissance Technologies's Q4 2019 Portfolio in Review
As of Q4 2019, Renaissance Technologies held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Renaissance Technologies's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Renaissance Technologies's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Renaissance Technologies fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Renaissance Technologies's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Renaissance Technologies opened 518 new positions and closed 443 in Q4 2019.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.